Optilume for urethral strictures Optilume is a novel drug-coated balloon that is indicated for the treatment of urethral strictures. The technology combines balloon dilation, to expand or widen the strictured area, and the delivery of an anti-proliferative drug (paclitaxel) intended to reduce the rate of stricture recurrence.
 
Status In progress
Process MT
ID number 565

Provisional Schedule

Stakeholder registration opens 04 October 2021
Scope published 15 November 2021
Committee meeting: 1 18 March 2022
Draft guidance: 1 08 April 2022 - 11 May 2022
Committee meeting: 2 17 June 2022
Resolution 18 July 2022
Expected publication 30 August 2022

Project Team

Project lead federica Ciamponi

Email enquiries

Stakeholders

Manufacturers Urotronic
Others Association of British Healthcare Industries (ABHI)
  Association of Healthcare Technology Providers for Imaging, Radiotherapy and Care (AXrEM)
  Boston Scientific
  Department of Health and Social Care
  Devices for Dignity
  Greater Manchester Health & Social Care Partnership
  Healthcare Improvement Scotland
  HealthTech Alliance
  Johnson & Johnson Medical Ltd
  Medical Technology Group
  Medicines and Healthcare Products Regulatory Agency
  University of Manchester Wounds Research Group
  NHS England
  The British In Vitro Diagnostics Association (BIVDA)
  NHS Digital

For further information on how we develop guidance, please see our page about NICE medical technologies guidance